Abbvie Inc Common Stock (ABBV) 59.86 $ABBV
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 115.63 (-1.75), MU: 13.21 (-0.84), PXD: 152.92 (-7.67), GILD: 80.47 (-2.90), EOG: 81.06 (-3.44), AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45), GOOGL: 685.20 (-29.67), CVX: 101.90 (-2.54), MSFT: 49.83 (-2.08)
AbbVie Declares Quarterly Dividend
PR Newswire - Thu Jun 16, 11:54AM CDT
The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.57 per share.
ABBV: 59.86 (-1.45)
AbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases
PR Newswire - Thu Jun 16, 7:00AM CDT
AbbVie, a global biopharmaceutical company, today announced the recipients of the AbbVie Crohn's & Colitis Scholarship and the AbbVie Rheumatology Scholarship. These scholarships provide financial support for exceptional students living with inflammatory bowel disease, including Crohn's disease or ulcerative colitis; rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis, as they pursue higher education goals.
ABBV: 59.86 (-1.45)
Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:45AM CDT
Infinity (INFI) announced disappointing results from the phase II DYNAMO study on duvelisib for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
PFE: 33.97 (-0.62), ABBV: 59.86 (-1.45), INFI: 1.32 (+0.02), BMY: 70.61 (-2.03)
Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:59AM CDT
Amgen's (AMGN) biosimilar version of AbbVie's best-selling drug, Humira, will face the FDA's Arthritis Advisory Committee.
AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45), BMY: 70.61 (-2.03), NVS: 77.10 (-3.57)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 76.98 (-4.68), ABBV: 59.86 (-1.45), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 229.02 (-9.60), SRPT: 18.52 (+0.64), ALXN: 112.99 (-10.58), AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45), REGN: 339.48 (-17.66), CELG: 96.29 (-4.37)
New AbbVie Global Campaign Aims to Provide Educational Resources for Millions Living with Painful, Chronic Skin Disease
PR Newswire - Tue Jun 07, 8:00AM CDT
AbbVie, a global biopharmaceutical company, today announced the launch of What's Your Sore Spot?, a disease education campaign to connect people impacted by hidradenitis suppurativa (HS), a painful, chronic, inflammatory skin disease,2 with educational resources designed to help them obtain an accurate diagnosis. The campaign, which is launching during HS Awareness Week (June 6 - 12), features WhatsYourSoreSpot.com, a gateway to more than two dozen country-specific websites with useful tools and resources about HS, including a symptom checker and discussion guide.
ABBV: 59.86 (-1.45)
AbbVie at ASCO: Early-Stage Data on ABT-414 and Rova-T
Arpita Dutt - Zacks Investment Research - Mon Jun 06, 10:21AM CDT
There was a lot of interest in the Rova-T data, considering AbbVie (ABBV) shelled out $5.8 billion and could pay up to an additional $4 billion to Stemcentrx under an acquisition agreement.
JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), ABBV: 59.86 (-1.45), BMY: 70.61 (-2.03)
AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Mon Jun 06, 8:00AM CDT
Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced longer-term follow-up results from Phase 3 studies of IMBRUVICA® (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Findings include an analysis of outcomes from the RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115) trials, which showed IMBRUVICA was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy (previously treated or treatment-naïve; abstract 7520). Other data include first-ever presentation of longer-term follow-up data from the HELIOS (CLL3001) trial showing IMBRUVICA in combination with bendamustine and rituximab (BR) continued to demonstrate superiority over time versus placebo plus BR in relapsed/refractory CLL/SLL patients (abstract 7525), along with improvements in quality of response.
ABBV: 59.86 (-1.45)
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Sun Jun 05, 8:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced safety and preliminary efficacy data from a Phase 1 study of ABT-414 - an investigational antibody drug conjugate (ADC) for epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM) - showed no dose-limiting toxicities and frequent, reversible ocular toxicities. Additionally, an estimated 30 percent (n=44) of patients treated with ABT-414 as monotherapy were progression free at six months [95% CI=17, 44] (secondary endpoint). These results, from an expansion cohort of one arm (Arm C) of a three-arm open-label study, were presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.1 Amplified EGFR is the most common genetic mutation associated with malignant GBM, an aggressive brain cancer.2
ABBV: 59.86 (-1.45)
Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC)
PR Newswire - Sun Jun 05, 6:30AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a confirmed overall response rate (ORR) of 39 percent and clinical benefit rate (stable disease or better) of 89 percent in patients with recurrent or refractory small cell lung cancer (SCLC), identified with high expression of DLL3. Rova-T demonstrated a one-year overall survival (OS) rate of 32 percent in the recurrent/refractory second- and third-line patient population. These new data were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago and featured in the "Best of ASCO" program, which presents scientific and educational highlights from the meeting. Less than one percent of all data abstracts are selected for this program.
ABBV: 59.86 (-1.45)
AbbVie to Highlight its Innovative Pipeline to the Investment Community
PR Newswire - Fri Jun 03, 7:09AM CDT
At an R&D Day meeting today for the investment community, AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present an overview of its innovative pipeline that reinforces AbbVie's strategy of delivering new therapies that significantly advance and reset the standard of care. Many current therapies in oncology, immunology, virology, neuroscience and women's health are insufficient in meeting the medical needs of patients. In addition, many of the diseases in these therapeutic areas are debilitating, life-threatening and cause a significant burden on healthcare systems around the world.
ABBV: 59.86 (-1.45)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 229.02 (-9.60), SRPT: 18.52 (+0.64), ICPT: 142.92 (-11.34), ABBV: 59.86 (-1.45), IONS: 21.97 (-1.63)
AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016)
PR Newswire - Thu Jun 02, 8:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients with rheumatologic diseases, will be presented at the Annual European Congress of Rheumatology (EULAR 2016), June 8 - 11, in London. These data add to the body of evidence supporting the safety and efficacy of adalimumab, an anti-TNF therapy, and AbbVie's continued commitment to innovation across immunology.
ABBV: 59.86 (-1.45)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 229.02 (-9.60), VRTX: 81.90 (-6.30), GILD: 80.47 (-2.90), SRPT: 18.52 (+0.64), ICPT: 142.92 (-11.34), ABBV: 59.86 (-1.45), IONS: 21.97 (-1.63)
Merck, AbbVie & Amgen Drugs a Step Closer to EU Approval
Arpita Dutt - Zacks Investment Research - Tue May 31, 7:16AM CDT
The CHMP issued a positive opinion for the regulatory applications submitted by Merck (MRK), Amgen (AMGN) and AbbVie (ABBV) for their respective drugs.
MRK: 55.88 (-1.80), PFE: 33.97 (-0.62), AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45)
AbbVie to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Tue May 31, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Thursday, June 9, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10:40 a.m. Central time.
ABBV: 59.86 (-1.45)
European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
PR Newswire - Tue May 31, 5:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission (EC) approved IMBRUVICA® (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia (CLL), expanding upon the initial EC approval in October 2014 for certain patients with CLL. This decision comes just one month after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued an opinion in favor of the use of IMBRUVICA for the treatment of adult patients with first-line chronic lymphocytic leukemia (CLL) in the European Union (EU).
ABBV: 59.86 (-1.45)
Stock Market News for June 22, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 9:10AM CDT
Benchmarks ended slightly higher on Tuesday as the latest Brexit polls tilted slightly in favor of the ‘remain’ camp
JNJ: 115.63 (-1.75), MU: 13.21 (-0.84), PXD: 152.92 (-7.67), GILD: 80.47 (-2.90), EOG: 81.06 (-3.44), AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45), GOOGL: 685.20 (-29.67), CVX: 101.90 (-2.54), MSFT: 49.83 (-2.08)
AbbVie Declares Quarterly Dividend
PR Newswire - Thu Jun 16, 11:54AM CDT
The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.57 per share.
ABBV: 59.86 (-1.45)
AbbVie Scholarship Programs Recognize Exceptional Students Living with Chronic Inflammatory Diseases
PR Newswire - Thu Jun 16, 7:00AM CDT
AbbVie, a global biopharmaceutical company, today announced the recipients of the AbbVie Crohn's & Colitis Scholarship and the AbbVie Rheumatology Scholarship. These scholarships provide financial support for exceptional students living with inflammatory bowel disease, including Crohn's disease or ulcerative colitis; rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis, as they pursue higher education goals.
ABBV: 59.86 (-1.45)
Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:45AM CDT
Infinity (INFI) announced disappointing results from the phase II DYNAMO study on duvelisib for the treatment of patients with refractory indolent non-Hodgkin lymphoma.
PFE: 33.97 (-0.62), ABBV: 59.86 (-1.45), INFI: 1.32 (+0.02), BMY: 70.61 (-2.03)
Amgen's Biosimilar of AbbVie's Humira to Face FDA Panel
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 9:59AM CDT
Amgen's (AMGN) biosimilar version of AbbVie's best-selling drug, Humira, will face the FDA's Arthritis Advisory Committee.
AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45), BMY: 70.61 (-2.03), NVS: 77.10 (-3.57)
Incyte's Jakafi Positive in Phase III for Polycythemia Study
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 8:15AM CDT
Incyte (INCY) announced new 28-week data from the phase III RESPONSE-2 study on Jakafi for the treatment of polycythemia vera.
INCY: 76.98 (-4.68), ABBV: 59.86 (-1.45), LLY: 74.33 (+0.39), BMY: 70.61 (-2.03)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 229.02 (-9.60), SRPT: 18.52 (+0.64), ALXN: 112.99 (-10.58), AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45), REGN: 339.48 (-17.66), CELG: 96.29 (-4.37)
New AbbVie Global Campaign Aims to Provide Educational Resources for Millions Living with Painful, Chronic Skin Disease
PR Newswire - Tue Jun 07, 8:00AM CDT
AbbVie, a global biopharmaceutical company, today announced the launch of What's Your Sore Spot?, a disease education campaign to connect people impacted by hidradenitis suppurativa (HS), a painful, chronic, inflammatory skin disease,2 with educational resources designed to help them obtain an accurate diagnosis. The campaign, which is launching during HS Awareness Week (June 6 - 12), features WhatsYourSoreSpot.com, a gateway to more than two dozen country-specific websites with useful tools and resources about HS, including a symptom checker and discussion guide.
ABBV: 59.86 (-1.45)
AbbVie at ASCO: Early-Stage Data on ABT-414 and Rova-T
Arpita Dutt - Zacks Investment Research - Mon Jun 06, 10:21AM CDT
There was a lot of interest in the Rova-T data, considering AbbVie (ABBV) shelled out $5.8 billion and could pay up to an additional $4 billion to Stemcentrx under an acquisition agreement.
JNJ: 115.63 (-1.75), PFE: 33.97 (-0.62), ABBV: 59.86 (-1.45), BMY: 70.61 (-2.03)
AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Mon Jun 06, 8:00AM CDT
Today, AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced longer-term follow-up results from Phase 3 studies of IMBRUVICA® (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Findings include an analysis of outcomes from the RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115) trials, which showed IMBRUVICA was associated with favorable progression-free survival (PFS) and overall survival (OS) regardless of line of therapy (previously treated or treatment-naïve; abstract 7520). Other data include first-ever presentation of longer-term follow-up data from the HELIOS (CLL3001) trial showing IMBRUVICA in combination with bendamustine and rituximab (BR) continued to demonstrate superiority over time versus placebo plus BR in relapsed/refractory CLL/SLL patients (abstract 7525), along with improvements in quality of response.
ABBV: 59.86 (-1.45)
AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting
PR Newswire - Sun Jun 05, 8:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced safety and preliminary efficacy data from a Phase 1 study of ABT-414 - an investigational antibody drug conjugate (ADC) for epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM) - showed no dose-limiting toxicities and frequent, reversible ocular toxicities. Additionally, an estimated 30 percent (n=44) of patients treated with ABT-414 as monotherapy were progression free at six months [95% CI=17, 44] (secondary endpoint). These results, from an expansion cohort of one arm (Arm C) of a three-arm open-label study, were presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.1 Amplified EGFR is the most common genetic mutation associated with malignant GBM, an aggressive brain cancer.2
ABBV: 59.86 (-1.45)
Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell Lung Cancer (SCLC)
PR Newswire - Sun Jun 05, 6:30AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that treatment with rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), demonstrated a confirmed overall response rate (ORR) of 39 percent and clinical benefit rate (stable disease or better) of 89 percent in patients with recurrent or refractory small cell lung cancer (SCLC), identified with high expression of DLL3. Rova-T demonstrated a one-year overall survival (OS) rate of 32 percent in the recurrent/refractory second- and third-line patient population. These new data were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago and featured in the "Best of ASCO" program, which presents scientific and educational highlights from the meeting. Less than one percent of all data abstracts are selected for this program.
ABBV: 59.86 (-1.45)
AbbVie to Highlight its Innovative Pipeline to the Investment Community
PR Newswire - Fri Jun 03, 7:09AM CDT
At an R&D Day meeting today for the investment community, AbbVie (NYSE: ABBV), a global biopharmaceutical company, will present an overview of its innovative pipeline that reinforces AbbVie's strategy of delivering new therapies that significantly advance and reset the standard of care. Many current therapies in oncology, immunology, virology, neuroscience and women's health are insufficient in meeting the medical needs of patients. In addition, many of the diseases in these therapeutic areas are debilitating, life-threatening and cause a significant burden on healthcare systems around the world.
ABBV: 59.86 (-1.45)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 229.02 (-9.60), SRPT: 18.52 (+0.64), ICPT: 142.92 (-11.34), ABBV: 59.86 (-1.45), IONS: 21.97 (-1.63)
AbbVie's Research and Commitment to Helping People Living with Rheumatologic Diseases Highlighted at the Annual European Congress of Rheumatology (EULAR 2016)
PR Newswire - Thu Jun 02, 8:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and research, including real-world evidence, aiming to improve clinical outcomes for patients with rheumatologic diseases, will be presented at the Annual European Congress of Rheumatology (EULAR 2016), June 8 - 11, in London. These data add to the body of evidence supporting the safety and efficacy of adalimumab, an anti-TNF therapy, and AbbVie's continued commitment to innovation across immunology.
ABBV: 59.86 (-1.45)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 229.02 (-9.60), VRTX: 81.90 (-6.30), GILD: 80.47 (-2.90), SRPT: 18.52 (+0.64), ICPT: 142.92 (-11.34), ABBV: 59.86 (-1.45), IONS: 21.97 (-1.63)
Merck, AbbVie & Amgen Drugs a Step Closer to EU Approval
Arpita Dutt - Zacks Investment Research - Tue May 31, 7:16AM CDT
The CHMP issued a positive opinion for the regulatory applications submitted by Merck (MRK), Amgen (AMGN) and AbbVie (ABBV) for their respective drugs.
MRK: 55.88 (-1.80), PFE: 33.97 (-0.62), AMGN: 146.45 (-5.82), ABBV: 59.86 (-1.45)
AbbVie to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Tue May 31, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 37th Annual Global Healthcare Conference on Thursday, June 9, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10:40 a.m. Central time.
ABBV: 59.86 (-1.45)
European Commission Approves IMBRUVICA® (ibrutinib) for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia
PR Newswire - Tue May 31, 5:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission (EC) approved IMBRUVICA® (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia (CLL), expanding upon the initial EC approval in October 2014 for certain patients with CLL. This decision comes just one month after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued an opinion in favor of the use of IMBRUVICA for the treatment of adult patients with first-line chronic lymphocytic leukemia (CLL) in the European Union (EU).
ABBV: 59.86 (-1.45)
